Casein kinase 1α (CSK1α), encoded by CSKN1A1 and negative regulator of Wnt/β-catenin and p53 signaling pathways [75], was highly expressed in newly diagnosed AML, and the survival analysis of AML patients using a TCGA-LAML database showed that CSKN1A1 mRNA expression was correlated with the survival of AML patients. The gene discussed is TP53; the disease is acute myeloid leukemia.